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INTRODUCTION

that Escherichia coli and other enteric bacteria produce
Shiga-like toxins (82; A. D. O'Brien, M. E. Chen, R. K.
Holmes, J. Kaper, and M. M. Levine, Letter, Lancet i:702,
1983); (v) appreciation that Vero cytotoxins and Shiga-like
toxins are the same (A. D. O'Brien, T. A. Lively, M. E.
Chen, S. W. Rothman, and S. B. Formal, Letter, Lancet
i:702, 1983); (vi) purification of Shiga-like toxin to homogeneity (80); (vii) demonstration that production of Shiga-like
toxins can be controlled by phage conversion (84, 108; S. M.
Scotland, H. R. Smith, G. A. Willshaw, and B. Rowe,
Letter, Lancet ii:216, 1983); (viii) cloning and characterization of the structural genes for Shiga-like toxin from
toxinogenic coliphages (44, 78, 119); (ix) demonstration of
antigenic heterogeneity among Shiga-like toxins (110; S. M.
Scotland, H. R. Smith, and B. Rowe, Letter, Lancet
ii:85-886, 1985; M. A. Karmali, M. Petric, S. Louie, and R.
Cheung, Letter, Lancet i:164-165, 1986); and (x) association
of Shiga-like toxin-producing strains of E. coli with hemorrhagic colitis (W. M. Johnson, H. Lior, and G. S. Bezanson,
Letter, Lancet i:76, 1983; A. D. O'Brien, T. A. Lively,
M. E. Chen, S. W. Rothman, and S. B. Formal, Letter,
Lancet i:702, 1983), and hemolytic uremic syndrome (HUS)
(52; M. A. Karmali, M. Petric, B. T. Steele, and C. Lim,
Letter, Lancet i:619-620, 1983). The primary goal of this
review is to provide an overview of the current status of the
rapidly evolving research on Shiga and Shiga-like toxins.

Although Shigella dysenteriae serotype 1 (Shiga) toxin

was discovered more than 80 years ago (18) and has long
been recognized as one of the most potent bacterial toxins
(18, 116), early efforts to characterize its structure, biologic

activity, genetics, role in pathogenesis, and other properties
by difficulties in preparing pure toxin, obtaining appropriate immunologic reagents, and conducting genetic studies with S. dysenteriae 1. The enterotoxicity of
Shiga toxin was first reported in 1972 (59). Other important
advances that have been made during the past decade
include the following: (i) purification of Shiga toxin to
homogeneity (7, 21, 81, 87, 120); (ii) identification of cell
surface receptors for toxin (8, 45; A. A. Lindberg, J. E.
Brown, N. Stromberg, M. Westling-Ryd, J. E. Schultz, and
K. A. Karlson, J. Bliol. Chem., in press; A. A. Lindberg,
J. E. Schultz, M. Westling, J. E. Brown, S. W. Rothman,
K. A. Karlsson, and N. Stromberg, Proc. FEMS Meet. Mol.
Biol. Pathogenic Microorganisms, in press); (iii) demonstration that the intracellular action of toxin causes an inhibition
of protein synthesis (7, 8a, 97, 111; T. G. Obrig, T. P. Moran,
were hindered

and J. E. Brown, J. Biol. Chem., in press); (iv) recognition
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susceptible target cells (9, 10, 97, 111), as discussed in a
subsequent section of this review.

History
Shigellosis, the severest form of which was historically
called bacillary dysentery, is a disease limited to humans and
certain other primates (24). The bacteria that cause
shigellosis belong to the genus Shigella and are classified
into four species and over 40 serotypes on the basis of the
characteristics of their 0 antigens. The species of Shigella
are S. dysenteriae (serogroup A), S. flexneri (serogroup B),
S. boydii (serogroup C), and S. sonnei (serogroup D).
Shigella spp. colonize the large bowel and must penetrate
and multiply within colonic epithelial cells to cause disease
in volunteers (25, 70). The pathophysiology of shigellosis is
beyond the scope of this review and is discussed in detail
elsewhere (57, 58). Typical symptoms of shigellosis include
cramps, painful defecation, fever, diarrhea, dysentery
(blood and mucus in stools), or diarrhea and dysentery (24).
All four species of Shigella have been shown to contain large
plasmids (120 to 140 megadaltons) that are required for the
organism to invade epithelial cells (101-104). At least three
chromosomally encoded determinants must also be expressed for shigellae to be fully virulent in animal models
(102), but the specific gene products made by them have not
been established.
Shigella spp. also elaborate a toxin, designated as Shiga
toxin, that may contribute to the development of necrotic
lesions of the colon. Several detailed reviews on Shiga toxin
have been published over the last 50 years (12, 30, 57, 58,
113, 116). The Shiga toxin was first described in 1903 by
Conradi, who reported that intravenous inoculation of
autolysates of Shiga's bacillus (Shigella dysenteriae 1) paralyzed and killed rabbits (18). It was subsequently shown
that various animal species exhibit differential susceptibilities to the lethal effects of Shiga toxin, but only the rabbit
and mouse display neurological symptoms (14). Studies in
the 1950s suggested that Shiga toxin does not act directly on
neurons (i.e., is not actually a neurotoxin) but that it can
cause secondary neurological disorders by its action on the
vascular system of the brain and spinal cord (6, 43). More
recent data concerning the interaction of Shiga toxin with
neurons are controversial. Wiley et al. (118) reported that
purified Shiga toxin can be axonally transported to rat vagal
sensory neurons and can kill those neurons. In contrast,
Brown et al. failed to demonstrate axonal transport of
purified Shiga toxin, nor were they able to show cytotoxicity
or specific binding of toxin to neuroblastoma hybrid cells
(J. E. Brown, W. H. Habig, J. G. Kenimer, and M. C.
Hardegree, Abstr. Annu. Meet. Am. Soc. Microbiol. 1985,
B109, p. 36). The reason for the diverse results of Wiley et
al. and Brown et al. is not apparent.
Although the paralytic-lethal effects of crude Shiga toxin
were originally demonstrated in the early part of this century, it was not until the 1940s that such preparations were
reported to be cytotoxic for selected mammalian cells (69,
115). Subsequently, Keusch et al. (59) showed that partially
purified preparations of Shiga toxin could elicit fluid accumulation, i.e., were enterotoxic, in ligated segments of
rabbit ileum. When purified Shiga toxin became available in
the 1980s, several groups independently demonstrated that
the paralytic-lethal, cytotoxic, and enterotoxic activities
described for extracts or culture filtrates of Shiga's bacillus
could be ascribed to a single toxin (7, 21, 28, 81). These
varied biological properties appear to reflect the molecular
action of Shiga toxin, i.e., inhibition of protein synthesis in

Purification and Structure
The following two points relevant to all purification
schemes should be emphasized: (i) Shiga toxin is a cellassociated toxin that may be located in the periplasmic space
(20, 37) and released into the culture medium after cell death
(23, 114); and (ii) the yield of Shiga toxin is increased if the
bacteria are cultured in a medium with a reduced iron
content or a medium that has been adjusted to a high pH (23,
79, 114). Purification of the Shiga toxin to homogeneity was
first reported in 1980 (81, 87), and several new and modified
purification procedures have subsequently been published
(7, 21, 80, 88, 120). The protocol for toxin purification now
used in our laboratory (80) is representative of the various
schemes. The shigellae are grown in an iron-depleted, modified glucose syncase broth (79, 82). The organisms are
harvested by centrifugation and lysed in a French pressure
cell, and the lysates are then clarified by ultracentrifugation
and passed over an Affi-Gel Blue (Bio-Rad Laboratories,
Richmond, Calif.) column. Toxin which binds to the Affi-Gel
Blue is eluted from the column and subsequently purified by
chromatofocusing and antitoxin affinity chromatography.
About 60% of the cytotoxin activity present in the starting
cell lysates is recovered, but the amount of purified protein
is low (100 to 200 pLg of toxin per 8 liters of culture). The
yield of purified toxin per 3 liters of culture as reported by
Olsnes et al. (88) was 150 ng with a recovery of 5%. By
contrast, Donohue-Rolfe et al. (21) reported yields of up to
800 1tg of purified protein toxin from 4 liters of culture
(recovery, 47%). In addition to the different yields of purified
Shiga toxin obtained by various investigators, a range of
values has been reported for the specific activity of purified
Shiga toxin as measured in 50% cytotoxic doses (CD50) per
milligram of toxin or 50% protein synthesis-inhibitory doses
(ID50) per milligram of toxin. The specific activities of
purified Shiga toxin published to date are 4 x 107 CD50/mg
(21), 3 x 108 CD50,/mg (7), 5 x 108 to 1 x 109 CD50/mg (79,
80), and 1 x 109 ID50/mg (88). These differences in specific
activity could reflect differences in sensitivity of the HeLa
cell sublines used to detect cytotoxin, variations among
laboratories in the method used to measure cytotoxicity, or
differences in the purity or extent of denaturation of the
various toxin preparations.
Past estimates of the molecular weight (MW) of purified
Shiga holotoxin have ranged from 58,000 to 70,000 (7, 21, 80,
88). The 70,000 value appears to be correct as calculated
from recent data on subunit MW and subunit stoichiometry.
The newest fidings indicated that Shiga toxin comprises one
A subunit of MW ca. 32,000 (21) and five copies (21) of a B
subunit of MW 7,700 (106). The mature B subunit consists of
69 amino acids (106) which agree exactly in composition and
sequence with the 69 amino acids inferred from the nucleotide sequence (47a) of the gene for the B subunit of E. coli
Shiga-like toxin type I (SLT-I). The A subunit must be
nicked by a proteolytic enzyme and its disulfide bonds must
be reduced for it to form the enzymatically active A1
fragment of MW 27,000 (88). The subunit structure of
purified Shiga toxin is reminiscent of those of cholera toxin
and E. coli heat-labile toxin, but no antigenic cross-reactivity
is demonstrable between Shiga toxin and those toxins (81).
Nonetheless, Seidah et al. (106) have proposed on the basis
of amino acid sequence data that the B subunits of E. coli
heat-labile toxin and cholera toxin are distantly related to the
B subunit of Shiga toxin.
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Although some strains of S. flexneri and S. sonnei (61, 85)
produce very low levels of Shiga-like toxin that is neutralizable by anti-Shiga toxin, this toxin has not yet been obtained
in pure form. O'Brien and LaVeck used a solid-phase
radioimmunoassay to measure the amounts of toxin antigen
produced by Shigella spp. other than S. dysenteriae 1 (79).
Their results indicated that the variations in levels of
cytotoxin produced by the different shigellae reflect differences in toxin yields rather than variations in cytotoxicity
per unit of toxin antigen. The question remains whether the
Shiga-like toxins of some S. flexneri and S. sonnei isolates
and the Shiga toxin of S. dysenteriae 1 are identical toxins or
different but closely related toxins. Until amino acid or
nucleotide sequence data are available for comparison of the
proteins or structural genes of the Shigella toxins, it is
appropriate to continue to use the term Shiga-like to describe
toxins neutralized by anti-Shiga toxin that are produced by
Shigella serotypes other than S. dysenteriae 1.
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proposed that two other binding sites for Shiga toxin exist on
HeLa cells (one tunicamycin sensitive and one tunicamycin
resistant), but neither is a functional receptor. A subsequent
publication (45) from that laboratory reported that a
nonfunctional, glycolipid receptor (presumably the
tunicamycin-resistant receptor) for HeLa cells had been
isolated and identified as a globotriaosylceramide. Lindberg

BD

EXTERNAL TOXIN

Mode of Action

Each subunit of Shiga toxin plays an essential role in the
intoxication of sensitive mammalian cells. The B subunit is
responsible for the binding of toxin to the mammalian cell
receptor, whereas the A subunit, after it is proteolytically
nicked and reduced to the Al fragment, is the component
responsible for inhibiting protein synthesis in the target cell.
With respect to the localization on different subunits or
domains of the functions that mediate toxic activity and cell
binding, Shiga toxin is similar to many other bifunctional
bacterial toxins such as cholera toxin, E. coli heat-labile
toxin, diphtheria toxin, Pseudomonas exotoxin A, and
pertussis toxin (75). Details of the mode of action of Shiga
toxin are given below and are represented diagramatically in
Fig. 1.
Receptor binding and internalization. Several reviews have
been published in which the receptor-mediated binding and
internalization of Shiga toxin by mammalian cells is discussed (26, 56, 75, 89). Keusch and Jacewicz (62) first
demonstrated the specific binding of toxin to rat liver membranes and to HeLa cells by means of an indirect assay
which measures the reduction of cytotoxicity in cell culture
medium. In the same study (62), the chemical nature of the
Shiga toxin receptor was analyzed. The receptor was destroyed by proteolytic enzymes, phospholipases, and
lyzozyme but not by neuraminidase or galactose oxidase.
Chitin-containing compounds competitively inhibited Shiga
toxin binding to HeLa cells, and wheat germ agglutinin,
which is known to possess specific binding affinity for
N,N',N"'-triacyl chitotriose, blocked toxin uptake as assessed by an indirect toxin consumption assay. Keusch and
Jacewicz (62) surmised from these data that the receptor for
Shiga toxin on mammalian cells may be a glycoprotein. It
should be noted that Lindberg et al. (J. Biol. Chem., in
press) were unable to confirm that chiotriose derivatives
inhibit the binding of Shiga toxin to HeLa cells when they
used a direct binding assay. Recently, Keusch et al. (63)
reexamined the chemical nature of the Shiga toxin receptor
with purified 1251I-labeled toxin as a probe to measure toxin
binding to HeLa cells. They concluded that the functional
receptor (defined as the receptor that mediates the cytotoxic
effect of Shiga toxin) is an N-linked glycoprotein on the basis
of a series of experiments in which they examined the effects
of trypsin, tunicamycin, ,-galactosidase, ,3-N-acetyl
glucosaminidase, and various sugars and lectins on toxin
binding and cytotoxicity. In that report (63), Keusch et al.

FIG. 1. Model for the receptor-mediated endocytic entry of

Shiga toxin and processing of Shiga toxin in a mammalian cell
(adapted from reference 57, Fig. 6). Shiga toxin enters the cell by
receptor-mediated endocytosis. The B subunit of the toxin binds to

the mammalian cell receptor. The clathrin-coated pit is pinched off,
and the coated vesicle is formed. The vesicle is acidified, and it may
fuse with lysosomes. The mechanism by which the enzymatically
active A1 fragment of Shiga toxin is generated and reaches the
cytosol is not known but is presumed to involve proteolytic nicking
and reduction of disulfide bonds of the A subunit. The A1 fragment
within the cytosol binds to the 60S ribosome, leading to inhibition of
protein synthesis and cell death.
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and co-workers (8; Lindberg et al., J. Biol. Chem., in press)
have also isolated and characterized Shiga toxin receptors
from HeLa cells. Lindberg et al. (J. Biol. Chem., in press)
studied the binding of purified Shiga toxin to a series of
glycolipids and to cells by using inhibition with synthetic
receptor analogues. These investigators proposed that the
functional HeLa cell receptor is a galactose al -* 4 galactose
(i.e., galabiose)-containing glycolipid but that glycoproteins
containing galabiose may mediate toxin binding without
toxin internalization (i.e., are nonfunctional receptors).
Thus, both Keusch and co-workers and Lindberg and coworkers agree that Shiga toxin can specifically bind to
galabiose-containing glycolipids and galabiose-containing
glycoproteins on HeLa cells. The two groups disagree on
which of the receptors are the functional receptors for toxin.
Whatever the exact chemical nature of the Shiga toxin
receptors on HeLa cells, indirect evidence suggests that the
B subunit of Shiga toxin binds to those receptors; monoclonal antibodies to the B subunit of Shiga toxin block the
binding of "251-labeled native toxin to the HeLa cell surface
(21). The isolated B subunit does not bind to intact HeLa
cells (88) but does bind to the glycolipid receptor extracted
from those cells (45). A glycolipid identified as a
globotriaosylceramide (45) that binds 125I-labeled Shiga toxin
has been isolated from rabbit jejunum and may be the same
as the microvillus membrane-binding site described by
Fuchs et al. (32). Expression of this glycolipid receptor on
rabbit intestinal microvillous membranes increases with the
age of the rabbit (M. Mobassaleh, A. Donohue-Rolfe, R. K.
Montgomery, G. T. Keusch, and R. J. Grand, Program
Abstr. 25th Intersci. Conf. Antimicrob. Agents Chemother.,
abstr. no. 323, 1985). This observation on the developmental
expression of Shiga toxin intestinal receptors may explain
why ligated segments of newborn-rabbit ileum are resistant
to the secretory effects of Shiga toxin (M. Mobassaleh, A.
Donohue-Rolfe, R. K. Montgomery, R. J. Grand, and G. T.
Keusch, Gastroenterol. Abstr., in press).
Only certain sublines of HeLa and Vero cells are highly
sensitive to Shiga toxin (35, 87); Hep-2 cells are slightly
sensitive to the toxin, whereas WI-38 cells, baby hamster
kidney cells, Chinese hamster ovary cells, Y-1 adrenal cells,
L cells, and a human melanoma cell line are refractory to
Shiga toxin (35, 87). Eiklid and Olsnes (27) observed that
125I-labeled Shiga toxin bound to toxin-sensitive cell lines
and to some, but not all, toxin-insensitive lines. These
findings indicate that the presence of toxin receptor on a
eucaryotic cell is necessary but not sufficient for Shiga toxin
to kill that cell; toxin must be internalized and must reach its
ribosome target. Shiga toxin appears to enter toxin-sensitive
HeLa cells by an endocytotic mechanism (29, 46, 89).
Inhibition of protein synthesis. Several groups of investigators have demonstrated that Shiga toxin inhibits protein
synthesis in eucaryotic cells (8a, 9, 10, 86, 97, 111). Analysis
of the mechanism by which Shiga toxin inhibits protein
synthesis has been modeled on previous studies of the mode
of action of other bacterial toxins. The prototype protein
synthesis-inhibiting bacterial toxins are diphtheria toxin and
Pseudomonas exotoxin A (75). These toxins inactivate elongation factor 2 (EF-2) by NAD-dependent adenosine
diphosphate (ADP) ribosylation of a modified histidine residue called diphthamide (75); inactivation of EF-2 inhibits
peptide chain elongation. Although Shiga toxin also inhibits
peptide chain elongation (10, 97), Obrig et al. (in press) found
that Shiga toxin does not directly affect EF-2 but does affect
EF-1-dependent reactions. Thus, Obrig et al. (in press) and
Brown et al. (8a) concluded that EF-1-dependent aminoacyl
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transfer ribonucleic acid (tRNA) binding is the primary site
of Shiga toxin action. How Shiga toxin alters EF-1dependent steps in protein synthesis remains to be determined. One possible explanation proposed by Obrig et al. (in
press) is that Shiga toxin structurally modifies 60S ribosomal
subunits, which results in reduced affinity of EF-1 (and
subsequently EF-2) for the ribosome. Obrig et al., in a
separate report (86), found that Shiga toxin exhibits ribonuclease (RNase) activity with naked 5S or 5.8S ribosomal
RNA (rRNA) of 60S ribosomal subunits acting as substrates;
28S rRNA was not tested. In the same report, Obrig et al.
presented evidence that two other ribosome-inactivating
toxins, ricin and phytolaccin, also exhibit RNase activity
specific for 5S or 5.8S rRNA as substrates (86). However,
the three toxins generated distinct patterns of RNA fragments, which suggests different cleavage sites on the RNAs.
As discussed by Obrig et al. (86), one possible explanation
for the findings with Shiga toxin is that the toxin preparation
contained a contaminating RNase. The argument presented
by Obrig et al. (86) against such a possibility was that the
heat inactivation profiles for the RNase and protein synthesis-inhibitory activities of Shiga toxin were similar. It should
be noted that despite the apparent RNase activity of Shiga
toxin against naked rRNA, no changes in any of the three
rRNAs present in intact ribosomes after exposure to Shiga
toxin have been observed (Obrig et al., in press).
Immunology and Immunochemistry
Evidence that Shiga and Shiga-like toxins are produced in
vivo in sufficient quantities to elicit an immune response was
first presented by Keusch and Jacewicz (60). These investigators reported that the sera of patients with shigellosis due
to either S. flexneri or S. sonnei contained antibody that
could neutralize the cytotoxic effects of Shiga toxin on HeLa
cells. In the same study, Shiga toxin-neutralizing antibody
responses in patients with previous S. dysenteriae 1 and S.
dysenteriae 2 infections were also demonstrated. The antiShiga toxin response in serum for both natural and experimental infections of humans was reported to be restricted to
the immunoglobulin M heavy-chain class (64). The neutralizing antitoxin in hyperimmune rabbit sera has been reported
as being restricted to the immunoglobulin M fraction (64) and
the immunoglobulin G fraction (81). The basis for these
discrepant results has not been found.
The question of whether secretory immunoglobulin A
anti-Shiga toxin antibodies in the gastrointestinal tract will
protect against diarrhea or dysentery caused by Shigella
spp. has not been resolved. However, it is clear from studies
with rhesus monkeys that high levels of circulating antiShiga toxin antibodies will not protect against oral Shigella
infection (74). Monkeys that were vaccinated parenterally
with Formalin-inactivated Shiga toxin developed levels of
antitoxin in serum which protected them against injection
with 1,000 50% mouse lethal doses, but they had diarrhea or
dysentery as severe as (or more severe than) unimmunized
controls did when they were fed S. dysenteriae 1.
Two types of antigenic variants could potentially exist
among the family of Shiga and Shiga-like toxins: (i) toxins
that are not cross-neutralized by a single reference antiserum, and (ii) partially cross-reacting toxins that are crossneutralized but are not antigenically identical. No crossreacting variants have been detected among the Shiga toxins
produced by different strains of S. dysenteriae 1 (A. D.
O'Brien, L. R. M. Marques, and S. B. Formal, unpublished
observations). Prado et al. (95) examined sonic lysates of 35
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strains of shigellae and found that 86% of the lysates (other
than S. dysenteriae 1) could not be neutralized by anti-Shiga
toxin. Whether the cytotoxin(s) present in these strains are
related to Shiga toxin but are not cross-neutralizable remains
to be determined.
Genetics
Little historical information is available on the genetics of
Shiga toxin production. The only mutations reported to
affect the yield of shiga toxin are chlorate-resistant mutations in S. dysenteriae 1 (34) that reduce the level of
cytotoxin produced (64, 79). The mutations in those strains
were not mapped, nor was the mechanism by which they
reduced the yield of cytotoxin determined. In fact, the
chlorate-resistant mutants were originally (34) classified as
nontoxigenic rather than as low-level toxin producers, because the cytotoxicity assay used in the early 1970s was less
sensitive than that now available.
The genes for the Shiga toxin of S. dysenteriae 1 and the
Shiga-like toxin of S. flexneri appear to be located on the
chromosome; no evidence for toxin genes on plasmids or
bacteriophages of Shigella spp. has been found. Timmis et
al. (112) reported the first in vivo cloning of the Shiga toxin
determinant. These investigators generated a series of R'
plasmids in E. coli K-12 that carry sections of the S.
dysenteriae 1 chromosome. The plasmids were constructed
to carry portions of the S. dysenteriae 1 chromosome
previously demonstrated (102) for S. flexneri to correlate
with the ability of the organism to provoke fluid secretion in
rabbit ileal segments. The results of the study by Timmis et
al. (112) localized the Shiga toxin genes (designated sht) near
the "metB distal side of argE". The close linkage of sht to
argE is in some disagreement with the report of Sansonetti et
al. (102), who tentatively localized the region on the S.
flexneri chromosome for fluid production in rabbits as being
near the lysine decarboxylase (LDS)-negative locus and in
the rha-mtl region. Timmis et al. (112) offered two quite
plausible explanations for these differences in the localization of the toxin genes: the maps of S. dysenteriae 1 and S.
flexneri may not be exactly the same, and S. dysenteriae 1
may carry a second copy of sht. The latter possibility is
supported by the mention (112) of an unpublished finding
that a second determinant for cytotoxin production is carried
on an R'-asn plasmid that also carries the LDS-negative
locus of Shigella spp. Timmis et al. (112) stated that they had
successfully cloned the toxin determinants of the R'-argE
plasmid in vitro. It will be of considerable interest to
compare the operon structure and nucleotide sequence of sht
with the structural genes of E. coli SLT-I and E. coli SLT-II
(see below). Toward that end, the structural genes for Shiga
toxin have recently been cloned in our laboratory (N. A.
Strockbine, R. K. Holmes, and A. D. O'Brien, Abstr. Annu.
Meet. Am. Soc. Microbiol. 1987, B-39, p. 78).
Role of Toxin in Disease
The
Dysentery.
subject of the possible role of Shiga and
Shiga-like toxins in the pathogenesis of several Shigella- and
E. coli-associated diseases was recently reviewed by Cantey
(12). There is no direct proof that Shiga and Shiga-like toxins
function as important virulence factors, but there are circumstantial data to support that hypothesis. Dysentery in
volunteers fed an invasive, low-toxin-producing (64, 79),
chlorate-resistant mutant of S. dysenteriae 1 designated
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strain 725 was milder than the disease caused by the invasive, highly toxinogenic parent strain M131. The duration
and height of the fever and severity of the dysentery were
less in volunteers fed strain 725 than in those fed strain M131
(70). These clinical observations are in keeping with the idea
that the higher level of toxin produced by S. dysenteriae 1
than other Shigella spp. correlates with the more severe
disease caused by Shiga's bacillus; dysentery occurs more
commonly in patients infected with S. dysenteriae 1 than in
those infected with any other serotype of Shigella (57). One
explanation for how Shiga toxin promotes dysentery is that
toxin present free in the colonic lumen binds to colonic
epithelia and ultimately kills those cells by inhibiting protein
synthesis. Two lines of evidence support such a theory.
First, measurable toxin is found in human fecal specimens
from patients with S. dysenteriae 1 infection (19). Second,
Shiga toxin binds to and is cytotoxic for primary cultures of
human colonic epithelial cells (M. P. Moyer, S. W. Rothman, P. S. Dixon, and J. E. Brown, submitted for publication; M. P. Moyer, S. W. Rothman, and J. E. Brown, Abstr.
Annu. Meet. Am. Soc. Microbiol. 1985, B108, p. 36).
Diarrhea. The results of gut perfusion studies (100) done
with monkeys also provide evidence for a role of Shiga or
Shiga-like toxins in causing the watery diarrhea sometimes
seen during shigellosis (24). All S. flexneri-infected animals
showed decreased colonic absorption or net colonic secretion. However, animals with diarrhea also showed net secretion in the jejunum, whereas no jejunal secretion was
evident in monkeys with dysentery alone. No invasion of
jejunal tissues by Shigella spp. was found in any of the
animals, although invasion of the colonic epithelium occurred regularly. Subsequently, Kinsey et al. (65) showed
that monkeys inoculated intracecally with S. flexneri had
dysentery but not diarrhea. Thus, in monkeys, the diarrhea
of shigellosis appears to require a secretory response of the
small bowel superimposed on the colonic dysfunction. More
recent findings with humans (11) suggest that shigella diarrhea results from colonic dysfunction without evidence for
an increased small-bowel flow rate. Wherever the intestinal
site for the secretion responsible for shigella diarrhea, one
may postulate that the secretion is a consequence of toxin
produced by the Shigella spp.
If Shiga toxin is responsible for the diarrhea of shigellosis,
a key question is how can a protein synthesis-inhibiting toxin
elicit fluid secretion in the intestine? Shiga toxin does not
appear to act like cholera toxin or E. coli heat-labile toxin.
Although Shiga toxin can elevate the cyclic adenosine
monophosphate (cAMP) content of rabbit intestinal mucosa
(22), as can cholera toxin and E. coli heat-labile toxin,
Shiga-toxin-induced accumulation of cAMP does not occur
until long after fluid secretion begins (H. T. Paulk, A. 0.
Cardamone, G. S. Gotterer, and T. R. Hendrix, Gastroenterology 72:1164, 1977). Shiga toxin also does not appear to
act like E. coli heat-stable enterotoxin. Unpublished observations from collaborative studies with R. Guerrant indicate
that Shiga toxin does not increase the cyclic guanosine
monophosphate (cGMP) content of the rabbit ileum. An
alternative mechanism by which Shiga toxin could cause net
fluid secretion is to block (or inhibit) fluid absorption.
Indeed, Keenan et al. (55) recently reported that purified
Shiga toxin and purified E. coli Shiga-like toxin selectively
destroyed the mature absorptive epithelial cells of the rabbit
ileum. One can therefore propose that Shiga toxin binds to
mature absorptive epithelial cells through glycolipid receptors, inactivates protein synthesis in the host cells, and
ultimately causes the death of those cells. In this model,
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TABLE 1. Characteristics of E. coli enterotoxinsa
Mass of
subunits A

(kilodaltsnis)

anit

Immunogenic

Bioassays

(kilodaltons)

NoN of
A
A and B

70,000

28; 11.8
28; 11.8
32; 7.7

1; 5
ND
1; 5

Yes
Yes
Yes

SLT-II Protein

ND

ND

ND

Yes

STa
STb

2,000
5,000

Y1 or CHO cells; rabbit ileal loops
Y1 or CHO cells
HeLa or Vero cell cytotoxicity; rabbit
ileal loops; lethality to mice
HeLa or Vero cell cytoxicity; rabbit
ileal loops; lethality to mice
Suckling mouse
Weaned pig jejunal loops

Enterotoxinb

LT-I
LT-II
SLT-I

Structure

MW

86,000
NDC

Protein
Protein
Protein

Polypeptide
Polypeptide

Mode of action

gei

No
No

For recent reviews of the enterotoxins, see Guerrant et al. (39) and O'Brien and Nataro (83).
LT, Heat-labile toxins; ST, heat-stable toxins. For details about the recently characterized toxin
et al. (40, 41).
c ND, Not determined.

Adenylate cyclase production

Adenylate cyclase production
Protein synthesis inactivation
ND
Guanylate cyclase production
ND

a

b

diarrhea would result from inhibition of absorption rather
than from active secretion.
HUS. HUS was originally described by Gasser et al. (33)
as the association of hemolytic anemia, thrombocytopenia,
and acute renal failure. HUS can occur after infection with
S. dysenteriae 1 (36, 68, 96) or after infection with E. coli
serotypes, such as E. coli 0157:H7, that produce high levels
of Shiga-like (Vero) toxin (52, 91; Karmali et al., Letter,
1983). S. dysenteriae 1-associated HUS tends to be more
severe than E. coli-associated HUS.
The signs of HUS after Shiga infection include disseminated intravascular coagulation, renal microangiopathy, and
hemolytic anemia (68). In one study (68), 50% of the patients
with S. dysenteriae 1-associated HUS had endotoxemia as
assessed by the Limulus assay. These symptoms presage a
poor prognosis. The clinical manifestations of E. coli
0157:H7-associated HUS are the classic triad described by
Gasser et al. (33). Karmali et al. (52) have suggested that the
Shiga toxin of S. dysenteriae 1 or the Shiga-like toxin of E.
coli 0157:H7 may enter the bloodstream and cause damage
to vascular endothelial cells such as those in the kidneys.
This is an attractive hypothesis, because the damage to
vascular epithelium seen on autopsy of patients who have
died of HUS (68) resembles the histopathological damage to
small vessels in the central nervous systems of animals
inoculated with crude Shiga toxin (6, 14). An animal model
of HUS has not yet been developed, and the limited availability of purified toxin has hindered studies on the effects of
purified toxin in animals.
SHIGA-LIKE TOXINS IN E. COLI
History and Nomenclature
Several different toxins that act on the intestinal tract can
be produced by E. coli (Table 1). E. coli organisms that
cause diarrheal disease in humans and animals have been
classified into four groups (71). Enterotoxigenic E. coli
(ETEC) adhere to the mucosa of the small bowel and
produce a heat-labile toxin or heat-stable toxin or both.
Enteroinvasive E. coli (EIEC) do not produce heat-labile or
heat-stable toxin, but, like shigellae, they penetrate and
multiply within colonic epithelial cells. Enteropathogenic E.
coli (EPEC) were originally incriminated epidemiologically
as pathogens for infants and young children. EPEC belong to
a limited number of serotypes (71), and some EPEC strains
have been shown to adhere avidly to the mucosa of the small

LT-II, see Pickett et al. (93), Holmes et al. (42), and Guth

intestine and produce characteristic effacement of microvilli
(1, 16, 77, 99). Enterohemorrhagic E. coli (EHEC) cause
hemorrhagic colitis and are of the serotype 0157:H7 (98).
EPEC and EHEC are not enteroinvasive and do not produce
the classical heat-stable and heat-labile enterotoxins (71, 98,
117). We and others (12, 52, 73) have proposed that some
EPEC and all EHEC strains may cause intestinal disease by
producing elevated levels of Shiga-like cytotoxins. In this
section, the discovery and nomenclature of E. coli Shiga-like
toxins, as well as the relationship of the toxins to Vero
toxins, will be discussed.
Discovery that EPEC and EHEC make Shiga-like toxins.
The initial search for a Shiga-like toxin of E. coli focused on
EPEC that caused diarrhea in infant rabbits (13) or infant
humans, because no virulence mechanism was established
for EPEC, and, as mentioned above, they are neither
enteroinvasive nor able to produce heat-labile or heat-stable
enterotoxins. The results of a preliminary survey of selected
E. coli strains for production of a Shiga-like toxin (defined at
that time as a cytotoxin for HeLa cells that could be
neutralized by rabbit antitoxin raised against crude Shiga
toxin) indicated that certain EPEC can make such a toxin
(A. D. O'Brien, M. R. Thompson, J. R. Cantey, and S. B.
Formal, Abstr. Annu. Meet. Am. Soc. Microbiol. 1977,
B103, p. 32). This hypothesis was confirmed in 1982 (82),
when monospecific antibody to Shiga toxin became available. In the same investigation (82), it was also observed that
the level of Shiga-like toxin produced by E. coli strains
varied from trace amounts that were detectable only in
bacterial lysates to levels equivalent to that produced by S.
dysenteriae 1.
That EHEC also make Shiga-like toxins was first reported
in 1983. O'Brien et al. (A. D. O'Brien, T. A. Lively, M. E.
Chen, S. W. Rothman, and S. B. Formal, Letter, Lancet
i:702, 1983) found that isolates of E. coli 0157:H7 isolated
during outbreaks that had occurred in the United States
made high levels of a cell-associated cytotoxin for HeLa and
Vero cells that could be neutralized by rabbit anti-Shiga
toxin. In the same study, it was reported that culture
supernatants of E. coli 0157:H7 strains 931, 932, and 933
also contained a cytotoxin for HeLa and Vero cells that
could be completely neutralized by rabbit anti-Shiga toxin.
On further analysis of the 933 strain, it is now clear that this
organism makes two kinds of cytotoxins, one of which can
be neutralized by anti-Shiga toxin (110; Scotland et al.,
Letter, 1985). We have designated (110) the anti-Shiga toxin
neutralizable cytotoxin as Shiga-like toxin I (SLT-I), and we
have named the other cytotoxin Shiga-like toxin II (SLT-II).
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It is important to note that SLT-I predominates in cell
lysates and SLT-II is the more active toxin in culture filtrate
(110) when both toxins are produced by the same strain.
Relationship of Shiga-like toxins to Vero toxins. The first
description of an EPEC Vero toxin was made in 1977 by
Konowalchuk et al. (67). The Vero toxin produced by the
strain used as a prototype in that classical study, EPEC
026:H11 strain H-30, appears to be the same toxin as SLT-I
of E. coli (A. D. O'Brien, T. A. Lively, M. E. Chen, S. W.
Rothman, and S. B. Formal, Letter, Lancet i:702, 1983).
Konowalchuk et al. identified nine strains in addition to E.
coli H-30 that contained a Vero toxin in culture filtrates of
the organisms (67). Of these 10 strains, 7 were associated
with diarrhea in human infants, 1 was associated with
diarrhea in a weanling pig, and 2 were isolated from cheese.
None of the E. coli strains that made Vero toxin also made
E. coli heat-labile or heat-stable enterotoxin. Vero toxin
from 8 of the 10 strains was neutralized by antiserum against
the Vero toxin from E. coli H30; Vero toxins from an EPEC
0128:B12 and from the pig isolate 0138:K81 were not
neutralized by the antiserum. This was the earliest indication
that E. coli strains produce more than one toxin active
against Vero cells.
The first studies on E. coli isolated from animals Vero
toxin concentrated on EPEC and EPEC-like strains (see
above) (15, 53, 54, 66, 105; W. G. Wade, B. T. Thom, and N.
Evans, Letter, Lancet ii:1235-1236, 1979; S. M. Scotland,
N. P. Day, G. A. Willshaw, and B. Rowe, Letter, Lancet
i:90, 1980; M. W. Wilson and K. A. Bettelheim, Letter,
Lancet i:201, 1980). Subsequently, Johnson et al. (Letter,
1983) found that Canadian isolates of EHEC which had been
incriminated as the agents of hemorrhagic colitis made Vero
toxin. As was the case with E. coli 0157:H7 strains isolated
during two outbreaks of hemorrhagic colitis in the United
States (98, 117), the Canadian strains were not
enteroinvasive and did not make E. coli heat-labile or
heat-stable enterotoxin. With the observation that EHEC
make a Shiga-like toxin active on Vero cells (A. D. O'Brien,
T. A. Lively, M. E. Chen, S. W. Rothman and S. B. Formal,
Letter, Lancet i:702, 1983), O'Brien et al. concuded that
Vero toxin and Shiga-like toxin were the same toxin. When
it was subsequently realized that EHEC can make more than
one antigenically distinct Vero toxin (110; Scotland et al.,
Letter, 1985), Scotland et al. adopted the nomenclature Vero
toxin 1 (VT1) and Vero toxin 2 (VT2). VT1 is equivalent to
SLT-I, and VT2 is synonymous with SLT-II.
Purification and Structure

SLT-Is from cell lysates of EPEC strain H-30 and from
cell lysates of EHEC strain 933 have been purified to
homogeneity in our laboratory (80; A. D. O'Brien, T. A.
Lively, T. W. Chang, and S. L. Gorbach, Letter, Lancet
ii:573, 1983) by the same series of steps used to purify toxin
from S. dysenteriae 1: i.e., French pressure cell disruption of
bacteria grown in iron-depleted medium, Affi-Gel Blue chromatography, chromatofocusing, and anti-Shiga toxin affinity
chromatography. The SLT-I from EHEC has also been
purified by a method that includes ammonium sulfate fractionation, DEAE-cellulose column chromatography, and
high-pressure liquid chromatography (M. Noda, N.
Nakabayaski, T. Yutsudo, T. Hirayama, and Y. Takeda,
Abstr. Toxicon 23:600, 1985). Each SLT-I purified from
these EPEC and EHEC strains was comprised of an A
subunit and multiple copies of a B subunit.
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The relative mobilities on sodium dodecyl sulfatepolyacrylamide gel electrophoresis of the A and B subunits
of the SLT-Is purified from EPEC strain H30 and EHEC
strain 933 were indistinguishable from those of the purified
Shiga toxin of S. dysenteriae 1 strain 60R when all three
samples were run in parallel (O'Brien, et al., Letter, Lancet
ii:573, 1983). This observation, together with the data now
available on the subunit structure of Shiga toxin (see above)
and the translated nucleotide sequence of SLT-I from EHEC
strain 933 (see Genetics and Regulation), indicate that the
SLT-I A subunit has a MW of 32,200 and the SLT-I B
subunit has a MW of 7,700. The value for the A subunit MW
is close to that of the original estimate obtained with purified
toxin of EPEC strain H30 (31,500 [80]), but the value for the
B subunit is almost twice that estimated from cross-linking
studies (80). By analogy with Shiga toxin, the most likely
A-to-B subunit ratio for SLT-I is 1:5. If that is indeed the
case, then the MW of holotoxin is ca. 70,000. Previous
estimates of the MW of SLT-I have ranged from a low of
10,000 to 30,000 (67; W. G. Wade, B. T. Thom, and N.
Evans, Letter, Lancet ii:1235-1236, 1979) to a high of 48,000
(80). The reason for this range in the reported MW of SLT-I
is not known.
SLT-II may have been purified to homogeneity by Padhye
et al., who recently reported (90) that they had purified a
Vero cell cytotoxin from culture filtrates of E. coli 0157:H7
strain 932 by concentration of filtrates followed by molecular
sieve and anion-exchange chromatography. Since the Vero
cell cytotoxin prepared by Padhye et al. (90) was not
neutralized by anti-Shiga toxin, and since strain 932 produces both SLT-I and SLT-II (73), it seems reasonable to
presume that the material isolated by Padhye et al. is SLT-II.
Neutralization studies with anti-SLT-II must be done to
prove or disprove that hypothesis. One of the problems with
isolating one type of SLT from E. coli strains that make both
SLT-I and SLT-II is that a toxin preparation could be
contaminated with the variant toxin. Indeed, with the discovery by Scotland et al. (Letter, 1985) that E. coli 933
makes not only VT1 (SLT-I) but also VT2 (SLT-II), we
reexamined our SLT-I preparation from E. coli 933 for
SLT-II. We found no evidence that our preparation of SLT-I
was contaminated with SLT-II.
Mode of Action
Purified SLT-Is from E. coli H30 (80) and E. coli 933
(O'Brien et al., Letter, Lancet ii:573, 1983) have the same
biological activities as and comparable specific activities to
purified Shiga toxin: cytotoxicity for HeLa and Vero cells,
enterotoxicity for ligated rabbit ileal segments, and lethality
at doses between 100 ng and 2 ,ug for mice. By analogy with
Shiga toxin, the molecular basis for these three seemingly
diverse biological activities is catalytic inactivation of 60S
ribosomes in toxin-sensitive (receptor-expressing) cells. To
our knowledge, the experiments to test the validity of this
analogy have not been done, although crude preparations of
E. coli SLT-I do inhibit protein synthesis in HeLa cells (81).
The receptor for SLT-I has been identified (C. A. Lingwood,
H. Law, S. Richardson, M. Petric, J. L. Brunton, and M.
Karmali, J. Biol. Chem., in press) and is the same as for
Shiga toxin. Cell lysates of the lysogenic strain E. coli C600
(933W) were recently used to assess the biological properties
of SLT-II (110). The results of that study indicate that
SLT-II has the same three biological properties as SLT-I,
but, per unit of protein in cell lysates, it is more lethal for
mice and less cytotoxic than SLT-I (110).
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Immunology and Immunochemistry
Recent studies have established that SLT-I and VT1 are
alternative names for the same toxin (110; Scotland et al.,
Letter, 1985; Karmali et al., Letter, 1986). SLT-I was
purified to apparent homogeneity from both EPEC and
EHEC strains (80; O'Brien et al., Letter, Lancet ii:573,
1983). In immunodiffusion tests with anti-Shiga toxin, both
preparations of purified SLT-I gave lines of identity with
Shiga toxin. Two monoclonal antibodies raised against E.
coli SLT-I neutralized both homologous E. coli toxin and
purified Shiga toxin (109). Monoclonal antibodies against
Shiga toxin have also been isolated, but their reactivities
against purified SLT-I were not determined (21, 38). Systematic studies of cross-reactivity between Shiga toxin and
SLT-I from various strains of E. coli in immunobinding
assays were not performed, primarily because sufficient
quantities of the purified toxins were not available. Further
studies are needed to determine whether Shiga toxin and
SLT-I are immunochemically identical or whether there are
unique epitopes on SLT-I that are not present on Shiga
toxin, or vice versa.
Although the SLT-II of E. coli has cytotoxic, enterotoxic,
and lethal activities similar to those of SLT-I and Shiga toxin
(110), it is not neutralized by antiserum against purified Shiga
toxin or monoclonal antibodies against SLT-I. In contrast, it
is neutralized by antiserum prepared against a crude preparation of SLT-II. Antigenic diversity among Vero cytotoxins
of E. coli has also been documented, and VT2 has been
recognized that is not neutralized by anti-Shiga toxin but is
neutralized by antiserum against crude VT2 (Scotland et al.,
Letter, 1985; Karmali et al., Letter, 1986). Reference SLT-II
antiserum (110) neutralized the cytotoxicity of lysates from
E. coli E32511 (0157:H-), the prototype strain against which
the reference VT2 antiserum was raised (Scotland et al.,
Letter, 1985), indicating that SLT-II and VT2 are probably
alternate names for the same or closely related toxins. No
toxin that has been identified immunologically as SLT-II or
VT2 has been purified to homogeneity or characterized
structurally, nor has the mode of action of this toxin been
investigated (see preceding section). As noted above,
Padhye et al. (90) have purified a toxin from E. coli 932 that
is distinct from SLT-I, but the immunologic identity of this
toxin with SLT-II has not yet been established. The possibility that SLT-I and SLT-II have shared epitopes that are
not involved in neutralization of toxicity by antibody has not
yet been investigated.
There is preliminary evidence that E. coli from a variety of
sources may produce Vero cytotoxins of additional antigenic
types. The Vero cytotoxins produced by strains of E. coli
isolated from pigs with edema disease or neonatal pigs with
diarrhea were not neutralized by antisera that were active
against the cytotoxin(s) from E. coli strains from humans
(67, 108). Karmali et al. (Letter, 1986) prepared a reference
antiserum against a toxoid made from purified VT from E.
coli H-30 (which is known to produce VT1) and compared its
neutralizing activity with that of serum obtained from a
patient convalescing from HUS. In tests with culture filtrates
from a collection of E. coli strains from human and animal
sources, all of the toxins that were completely neutralized by
the antitoxoid (presumed to be VT1) were also neutralized
by the convalescent serum. However, the toxins that were
not neutralized by the antitoxoid could be divided into two
groups on the basis of their reaction with the convalescent
serum: some that were partially neutralized (and presumably
contained VT2 exclusively or in highest titer) and others that

213

were not neutralized at all. Karmali et al. interpreted the
data as supporting the existence of antigenically distinct VT1

and VT2 toxins produced by E. coli, a conclusion with which

we agree, but they did not address the nature of the toxin(s)
that were not neutralized by either of their antisera. Unpublished observations from our laboratory (L. R. M. Marques,

J. S. M. Peiris, S. J. Cryz, and A. D. O'Brien) suggest that
at least one Vero toxin from E. coli strains isolated from pigs
with edema disease is related to, but not identical with, the
prototype SLT-II. Such strains contain an extracellular Vero
toxin that, unlike SLT-II, is not active on HeLa cells but is
neutralized by reference antisera against SLT-II. How this
variant of SLT-II is related to the Vero toxins produced by
the strains described by Karmali et al. (Letter, 1986) and
Smith et al. (108) remains to be determined.
Genetics and Regulation
Phage conversion is responsible for controlling the production of several important bacterial toxins, including diphtheria toxin, streptococcal erythrogenic toxin, botulinum
toxin, and staphylococcal enterotoxin A (2, 5, 72). Toxinconverting phages contain genes that are essential for
toxinogenesis, and susceptible bacteria that become
lysogenic for such tox+ phages acquire the capacity to
produce the corresponding toxin. Recently, production of
Shiga-like toxins was also shown to be determined by
specific phages in selected strains of both EPEC (026, 0128)
and EHEC (0157) serotypes isolated from humans (84, 108;
Scotland et al., Letter, 1983; H. R. Smith, N. P. Day, S. M.
Scotland, R. J. Gross, and B. Rowe, Letter, Lancet
i:1242-1243, 1984). In contrast, production of Shiga-like
toxin in E. coli strains isolated from pigs was not found to be
controlled by phages (108).
The phages that determine the production of Shiga-like
toxins in E. coli are of several different types that were
initially distinguished on the basis of differences in properties such as host range, immunity specificity, and susceptibility to thermal inactivation (84, 108). E. coli H19 (026) and
933 (0157) are both lysogenic for two different toxinconverting phages. The phages, originally designated H19A
(108) and H19J (108) are independent isolates of the same
phage from strain H19 that are closely related to phage 933J
from strain 933 (108) in terms of their morphology, virion
polypeptides, DNA restriction fragments, and immunity
specificity, but phage H19B has a different immunity specificity. Phages H19A/J, 933J, and H19B are all lambdoid
phages that code for SLT-I. A 8.1-kilobase (kb) EcoRI
fragment of the H19B genome was shown to be homologous
with the region of the gene of phage lambda that encodes the
genes cI, ninR, 0, P, and the origin of replication (44); the
regions of homology between phage lambda and phages
H19A/J and 933J have not yet been mapped in detail. Phage
933W from E. coli 933 has quite different characteristics
from the other phages described above and codes for SLT-II
(84, 110). A converting phage was also isolated from an
0157:H- E. coli strain, E32511 (119), which was subsequently shown to produce SLT-II (110; Scotland et al.,

Letter, 1985).

expression of the operon for SLT-I
schematically in Fig. 2. The structural genes that
encode SLT-I were cloned on a 2.5-kb DNA fragment from
a phage from strain H19 (not characterized as H19A or
H19B) (119), on a 3.1-kb DNA fragment from phage 933J
(78), and on a 1.7-kb DNA fragment from phage H19B (44).
The restriction maps of phages 933J and H19B were similar
The organization and

are shown
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FIG. 2. Working model of the organization and expression of the SLT-I operon. The restriction map of the cloned 3.1-kb EcoRI-NcoI
fragment of DNA from phage 933J is adapted from Jackson et al. (47a). The genetic map shows the location for the promotor (P) for the SLT-I
operon and the structural genes slt-I A and slt-I B. The mRNA is presumed to be polycistronic. The primary translation products correspond
to the unprocessed A and B polypeptides of SLT-I which have amino-terminal signal sequences represented by the wavy lines. The oligomeric
holotoxin is presumed to be assembled from the A and B polypeptides after they are secreted and processed to remove the signal sequences.

but not identical. Analysis of appropriate DNA clones and
subclones from phage 933J in minicells (78) and from phage
H19B in an in vitro protein synthesis system (44) provided
direct evidence that the phage genomes code for SLT-I,
permitted assignment of the locations of the contiguous
sequences coding for polypeptides A and B, and provided
evidence for the orientation of transcription. Expression of
the B gene by clones from which the promoter and the
proximal part of the A gene was deleted indicated that the B
gene can also be transcribed from a second promoter. This
organization of the toxin operon was confirmed and extended by analysis of transposon insertions and mini-mu lac
operon fusions within the genes for SLT-I (119; R. J. Neill,
N. R. Serrano, S. W. Rothman, D. A. Foret, and D. H.
Wells, Abstr. Annu. Meet. Am. Soc. Microbiol. 1985, B112,
p. 36; D. L. Weinstein and A. D. O'Brien, Abstr. Annu.
Meet. Am. Soc. Microbiol. 1986, B24, p. 28). The complete
nucleotide sequence of the structural genes for the A and B
polypeptides of SLT-I and the adjacent regulatory sequences
fromn phage 933J have recently been determined in our
laboratory (47a), and preliminary results from the sequencing of the A and B subunit genes from phage H19B have been
reported by others (5). Analysis of the translated amino acid
sequences indicates that the A and B polypeptides of SLT-I
contain hydrophobic signal sequences at their amino termini
and are probably synthesized as precursor forms of secreted
periplasmic proteins. The deduced sequence for the mature
form of the B polypeptide of SLT-I was identical with the
69-amino-aid sequence determined recently for the B polypeptide of Shiga toxin from S. dysenteriae (106). These
studies therefore establish conclusively that SLT-I from E.
coli and Shiga toxin from S. dysenteriae 1 are very closely
related, and possibly identical, proteins.
The genetic determinants for a second Vero cytotoxin
(VT2) were cloned on a 4.7-kb EcoRI fragment from a phage
from E. coli E32511 into the plasmid vector pACYC184

(119). A 2-kb DNA probe prepared from the 4.7-kb insert of
this hybrid plasmid was shown to hybridize with toxinogenic
strains of E. coli 0157 that failed to react with another
0.75-kb DNA probe for the SLT-I structural genes, providing direct evidence for two genetically distinct cytotoxins of
E. coli. On the basis of evidence that E. coli E32511
produces SLT-II but not SLT-I (110; Scotland et al., Letter,
1985) and that E. coli K-12 lysogenized with the phage from
strain E32511 also produces SLT-II only (Scotland et al.,
Letter, 1985), it seems almost certain that th, second toxin
identified by genetic criteria is the same as the second toxin
identified by immunologic criteria. Under conditions of low
stringency, the 2-kb DNA probe for SLT-II cloned from the
E32511 phage hybridized weakly with the 0.75-kb DNA
probe for SLT-I (119), and the 3.1-kb DNA fragment encoding SLT-I from phage 933J described above hybridized with
specific restriction fragments of DNA from the SLT-IIconverting phage 933W (110). These observations indicate
that there is some homology between the structural genes for
SLT-I and SLT-II. Very recently, the SLT-II genes were
cloned and their polypeptide gene products were identified
(J. W. Newland, N. A. Strockbine, and R. J. Neill, submitted for publication). Sequencing of the genes for SLT-II is in
progress in our laboratory (M. P. Jackson, R. J. Neill, R. K.
Holmes, A. D. O'Brien, and J. W. Newland, mnanuscript in
preparation). Preliminary data based on the sequencing
indicate that the genes for SLT-I and SLT-II have approximately 50 to 60% overall homology, with some regions
having substantially greater homology. The molecular
masses of the processed A and B polypeptides of SLT-II are
predicted to be approximately 33.1 and 7.7 kilodaltons,
respectively.
Little is known about the regulation of production of
SLT-I or SLT-II in E. coli. For strains of E. coli that produce
both SLT-I and SLT-II, SLT-I is often the predominant
toxin present in cell lysates, whereas SLT-II may be present
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in much higher titer than SLT-I in culture supernatants (16).
This observation suggests that there may be significant
differences in secretion or localization of SLT-I and SLT-II
in E. coli. Wild-type strains of E. coli have been classified as
high-, moderate-, or low-toxin-producing strains on the basis
of quantitative titrations of toxin produced by strains grown
under rigidly controlled conditions in deferrated medium
(73). All strains of E. coli 0157:H7 associated with hemorrhagic colitis have been characterized as highly toxinogenic,
and a significant proportion of EPEC isolates are highly
toxinogenic. Most highly toxinogenic strains produce SLT-I,
and some also produce SLT-II. Production of SLT-II only is
common among strains classified as moderately toxinogenic
(73, 110). All strains of E. coli K-12 examined to date
produce low levels of Shiga-like toxin that can be neutralized
by polyclonal anti-Shiga toxin or monoclonal antibodies
against SLT-I, but the DNA probe for SLT-I from phage
933J described above does not hybridize to any significant
extent with DNA from E. coli K-12 strains. The reasons for
this apparent discrepancy between the results of immunologic and genetic tests for the SLT of E. coli K-12 strains
have not been resolved.
Role in Disease
Epidemiological evidence. As is the case with Shiga toxin,
there is no direct proof that E. coli SLT-I or SLT-II plays a
role in disease. Some of the strongest circumstantial evidence comes from epidemiological studies of E. coli strains
isolated from humans (17, 48a, 52, 73, 105, 108) and animals
(15, 53, 54, 73, 76, 107). Most of the epidemiological studies
to date have exclusively examined culture filtrates of bacteria for Vero toxin. By contrast, Marques et al. (73) recently
tested culture supernatants and sonic lysates of 418 strains of
E. coli isolated from human or animal stools or from food for
cytotoxic effects on HeLa cells. These investigators also
asked whether cytotoxicity could be neutralized by antiShiga toxin. Marques et al. (73) classified strains according
to the level of cell-associated toxin they produced. The
categories were as follows: low, 2 x 102 to 6 x 102 CD50 per
ml of sonic lysate; moderate, 1 x 103 to 1 x 104 CD50 per ml
of sonic lysate; and high, 1 x 105 to 1 x 108 CD50 per ml of
sonic lysate. Of the 418 strains analyzed, 107 had no detectable cell-associated cytotoxicity. A total of 262 strains made
low levels of cytotoxin. The culture supernatants from the
low-level cytotoxin producers had no detectable activity.
Strains that fell in the low-level toxin producer category
included E. coli isolated from healthy adults, E. coli K-12
substrains, EIEC, ETEC, E. coli strains of classical EPEC
serogroups isolated from patients with diarrhea, other
strains isolated from patients with diarrhea, and three strains
(not of the 0157:H7 serotype) isolated from patients with
hemorrhagic colitis. Ten strains produced moderate levels of
cell-associated cytotoxin, and cytotoxicity could also be
detected in culture supernatants. All 10 strains were associated with diarrhea, hemorrhagic colitis, or HUS, and the 10
strains made only SLT-II (110). A total of 39 strains made
high levels of cytotoxin, and 38 of the 39 were associated
with diarrhea, hemorrhagic colitis, or HUS. All 39 strains
made SLT-I, and 17 of the 39 strains also made SLT-II (110).
The finding that moderate or high levels of cytotoxin were
almost exclusively (48 of 49) found in strains isolated from
people with diarrhea, hemorrhagic colitis, or HUS suggests
that such elevated levels of cytotoxin may play a role in the
pathogenesis of these diseases. However, the mechanism by
which elevated levels of SLT-I or SLT-II or both might
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mediate these diseases has not been determined. It is also
not clear whether one of the two Shiga-like toxins is more
important than the other in the pathogenesis of each type of
enteric disease. It should be emphasized that low levels of
cytotoxin might also damage host cells if toxin were produced by an E. coli strain that could adhere avidly to or
invade intestinal epithelial cells.
With the realization that moderate- and high-level Shigalike toxin-producing strains are strongly associated with
enteric disease and HUS (48a, 52, 73) comes the need for an
efficient and sensitive means of detecting such strains in
stools. Karmali et al. (51) have described a method for
detecting low numbers of Vero toxin-producing E. coli in
mixed cultures by a combination of colony "sweeps" (loopfuls of confluent bacterial growth) and polymyxin extraction
of cell pellets. The advantages of this procedure are its
sensitivity and its capacity to detect both SLT-I and SLTII-producing strains of E. coli. The major disadvantage of the
procedure is the need to have tissue culture facilities available in the clinical laboratory. This is a particular problem
for small laboratories and for nearly all laboratories in
developing countries. A colony enzyme-linked immunosorbent assay that permits direct detection of high-level SLTI-producing E. coli on agar plates was recently described
(109). In that assay, cultures are grown on iron-depleted agar
supplemented with subinhibitory doses of trimethoprimsulfamethoxazole, an antimicrobial mixture that stimulates
Shiga and Shiga-like toxin synthesis (50). This observation
was made when Karch et al. (48) tested several antimicrobial
agents for their effects on toxin production. After samples
are inoculated onto the agar containing trimethoprimsulfamethoxazole, plates are incubated overnight, and bacterial colonies are then transferred to nitrocellulose by
blotting. Toxin is released from the colonies on the nitrocellulose with polymyxin B, and the toxin bound to the membrane is detected by addition of monoclonal antibody to the
B subunit of SLT-I, a horseradish peroxidase-coupled second antibody, and substrate. The advantages of the colony
enzyme-linked immunosorbent assay are its direct application to stool cultures and its sensitivity and specificity (109).
The disadvantage of the assay is that it will detect only E.
coli that produce high levels of SLT-I (109). A monoclonal
antibody specific for SLT-II will have to be developed and
incorporated into the assay to detect E. coli that make only
SLT-II.
Animal models. Several animal models have been developed for studying the virulence mechanisms of EHEC
0157:H7 (3, 4, 31, 92, 94; J. J. Farmer, M. E. Potter, L. W.
Riley, T. J. Barrett, P. A. Blake, M. L. Cohen, G. K.
Morris, B. M. Thompson, C. A. Bopp, A. Kaufmann, R. S.
Remis, and J. G. Wells, Letter, Lancet i:702-703, 1983) and
otherE. coli strains that produce elevated levels of Shigalike toxins (92). The infant rabbit, the gnotobiotic pig, and
the gnotobiotic calf (D. Francis, personal communication)
seem to be appropriate models for studying colonization and
induction of diarrhea after oral infection with E. coli
0157:H7 strains. The mechanism of colonization of the
gnotobiotic pig by E. coli 0157:H7 resembles the attach-andefface mode of classical EPEC (reviewed in reference 71),
except that colonization by EHEC of the gnotobiotic pig is
apparently not plasmid mediated (S. Tzipori and R. RobinsBrowne, personal communication). However, a large plasmid of 60 to 70 megadaltons is present in most isolates ofE.
coli 0157:H7 (117; Johnson et al., Letter, 1983), and that
plasmid is associated with the expression of a unique fimbrial
antigen (49).
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In a very interesting study by Pai et al. (92), it was
observed that 3-day-old rabbits inoculated intragastrically
with 108 E. coli 0157:H7 cells consistently developed diarrhea. The damage to the mucosal epithelium was seen
mainly in the mid- and distal colon and was characterized by
apoptosis (defined by Pai et al. [92] as "individual cell
death") in the surface epithelium, increased mitotic activity
in the crypts, mucin depletion, and a mild to moderate
infiltration of neutrophils in the lamina propria and epithelium. Pai et al. (92) also found that infant rabbits developed
diarrhea when given partially purified Vero toxin (isolated
from culture filtrates of E. coli 0157:H7 and therefore
probably predominately SLT-II). Furthermore, these investigators noted that the mucosal abnormalities of rabbits
inoculated with toxin alone mimicked those seen when the
intact organism was used. It is of note that apoptosis was a
striking feature of the histopathological damage to adult
rabbit ileum after exposure to purified Shiga toxin or SLT-I

(55).
SHIGA-LIKE TOXINS IN OTHER BACTERIA

Some strains of Vibrio cholerae and Vibrio parahaemolyticus make low levels of a cell-associated cytotoxin for
HeLa cells that can be neutralized by polyclonal anti-Shiga
toxin (A. D. O'Brien, M. E. Chen, R. K. Holmes, J. Kaper,
and M. M. Levine, Letter, Lancet, i:77-78, 1984) and
monoclonal antibody to the B subunit of SLT-I (109). We
have previously speculated (O'Brien et al., Letter, 1984) that
a Shiga-like toxin might be responsible for the diarrhea
occasionally seen with volunteers fed V. cholerae strains
that do not make cholera enterotoxin, such as JBK70 (47).
One of the ways to test this hypothesis is to construct V.
cholerae strains that no longer contain the Shiga-like toxin
genes and to compare the diarrhea-evoking potential of the
mutant with that of its parent. Experiments to produce such
mutants are in progress (J. Kaper, personal communication).
In addition to the Vibrio sp., a strain of Salmonella
typhimurium (82, 109) and several isolates of Campylobacter
jejuni (M. M. Moore, M. J. Blaser, G. I. Perez-Perez, and
A. D. O'Brien) have been found to produce low levels of a
cytotoxin neutralized by anti-Shiga toxin. The role, if any,
that these toxins play in the pathogenesis of salmonellosis
and campylobacteriosis remains to be determined. Moreover, the frequency of Shiga-like toxin synthesis by S.
typhimurium and C. jejuni is unknown. To date, no bacteria
other than E. coli have been shown to produce a cytotoxin
neutralized by reference anti-SLT-II sera.
CONCLUSION

The main purpose of this review was to summarize the
results of recent studies leading to the purification and
characterization of S. dysenteriae 1 toxin and the immunologically related E. coli Shiga-like toxin, as well as the
cloning and characterization of the structural genes for E.
coli SLT-I. Determination of the nucleotide sequences of the
structural genes and the corresponding amino acid sequences for the structural polypeptides for all known members of the Shiga toxin family in the near future is technically
feasible. Such studies will provide unequivocal evidence
about the extent of genetic and structural homology among
these toxins, but additional studies are required for detailed
knowledge concerning the three-dimensional structures of
the toxins and the relationships between structure, receptor-
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binding activity, mechanism(s) for inactivation of protein
synthesis, and biologically important antigenic determinants. The availability of the cloned toxin genes, highly
specific monoclonal antitoxic antibodies, and purified toxins
provides a powerful set of tools for molecular analysis of
these and other aspects of Shiga and Shiga-like toxins.
At present, the role of Shiga toxin in the pathogenesis of
infectious diseases caused by Shigella spp. remains highly
suggestive but inconclusive. No strains of S. dysenteriae 1
have been identified that are virulent but fail to produce
Shiga toxin. It should be feasible to produce genetically
engineered, isogenic strains of S. dysenteriae 1 that differ
only with respect to their toxinogenicity or nontoxinogenicity and to perform direct tests to determine whether the toxin
is an essential or an accessory virulence factor for the
pathogenesis of shigellosis. Analogous studies should also be
done with other Shigella species. All efforts to date to
prevent shigellosis by antitoxic immunity have been unsuccessful, but reliable methods for inducing secretory antitoxic
antibodies in the gut are not yet available.
Epidemiological studies have established that production
of high or moderate levels of Shiga-like toxins is associated
with many EPEC and most EHEC strains that cause disease
in humans. Furthermore, E. coli or Shigella strains that
produce high or moderate levels of toxin are frequently
isolated from patients with HUS. Most strains of E. coli that
cause edema disease in pigs also produce elevated levels of
Shiga-like toxin. Many of these studies do not differentiate
between the antigenic variants of Shiga-like toxins; therefore, additional studies are needed to define more precisely
the prevalence of SLT-I and SLT-II among such strains and
to establish whether other serotypes or serovariants exist
among the Shiga-like toxins of E. coli.
The observation that active immunization against Shiga
toxin does not provide protection against shigellosis in
experimental animals (74) does not provide definitive evidence against a pathogenic role for Shiga or Shiga-like
toxins. The pathogenesis of such infections involves several
different kinds of interaction between bacteria and host cells.
Shigella spp. are able to invade and multiple within colonic
epithelial cells, and EPEC become closely associated and
efface the microvilli of enterocytes. Toxin could be produced
in the intracellular environmnt or delivered to target cells by
direct contact with bacterial cells, and such toxin might not
be accessible to neutralization by antibodies in the extracellular milieu. The nature of the interaction between EHEC
and target cells in the intestines of infected humans is not yet
clearly defined. For HUS and edema disease, it has been
postulated that toxin may be disseminated hematogenously
from the intestinal tract and reach putative target cells such
as the vascular endothelium in distant organs. If toxin
released from bacterial cell has an essential or adjunctive
role in pathogenesis, then specific antitoxic immunity might
be effective for prevention or treatment of some of these
diseases.
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